OCULAR PHARMACOLOGY 2 Flashcards
The ideal volume of containers for ophthalmic drops should not be more than _____mL.
a. 5mL
b. 10mL
c. 15mL
d. 30mL
e. 60mL
B
The ideal content of containers for ophthalmic ointments should not be more than __ g.
a. 5g
b. 10g
c. 1g
d. 15g
e. 50g
A
mydriatic that can liberate pigmented cells in the anterior chamber.
a. Pilocarpine
b. Phenylephrine
c. Propranolol
d. Atropine
e. Carbachol
B
Part of patient’s history which can either enhance or preclude successful pharmacotherapy.
a. Chief complaint
b. Medication history
c. History of present illness
d. Family history
e. Social history
E
Preparations causing no epithelial damage:
a. Cocaine
b. Pilocarpine
c. Gentamicin
d. Atropine
e. Benzalkonium chloride
D
Preservative preferred by many manufacturers because of their stability, excellent antimicrobial properties in acid formulation, and long shelf life.
a. Chlorhexidine
b. Chlorobutanol
c. Mercurial
d. Sodium perborate
e. Benzalkonium chloride
E
This can be used as an antioxidant.
a. Chlorhexidine
b. Chlorobutanol
c. Mercurial
d. Sodium perborate
e. Benzalkonium chloride
E
This compound is converted to hydrogen peroxide and then oxygen and water once in the eye.
a. Chlorhexidine
b. Chlorobutanol
c. Mercurial
d. Sodium perborate
e. Benzalkonium chloride
D
It is not a highly effective preservative because it tends to disappear from bottles during prolonged storage.
a. Chlorhexidine
b. Chlorobutanol
c. Mercurial
d. Sodium perborate
e. Benzalkonium chloride
B
An agent other than the active drug or preservative added to a formulation to provide proper tonicity, buffering, and
viscosity to complement drug action.
a. Preservative
b. Surfactant
c. Buffer
d. Vehicle
e. Prodrug
D
This compound can create a complex with mercury, nicotine, cyanide, and other toxic materials to reduce their damaging effects.
a. Methylcellulose
b. Polyvinyl alcohol
c. Propylene glycol
d. Polyethylene glycol
e. Polyvinylpyrrolidone (povidone)
E
Some of its derivatives has a greater adhesion to mucins than do other viscous vehicles currently used in ocular formulations.
a. Methylcellulose
b. Polyvinyl alcohol
c. Propylene glycol
d. Polyethylene glycol
e. Polyvinylpyrrolidone (povidone)
A
They are soluble in water and are often used to improve solubility, stability, or irritability of various compounds.
a. Cyclodextrin
b. Emulsions
c. Polyacrylic acid
d. Propylene glycol
e. Polyethylene glycol
A
Blurred vision is one of the most frequent adverse effects from this ophthalmic dosage form.
a. Solution
b. Emulsion
c. Suspension
d. Ointment
e. Gel
D
practical advantage of this sustained delivery system is the once-daily dosage regimen, with the drug usually administered at bedtime.
a. Solution
b. Emulsion
c. Suspension
d. Ointment
e. Gel
E
Thin membranes of porcine or bovine scleral collagen that conform to the cornea when placed on the eye:
a. collagen inserts
b. collagen shields
c. liposomes
d. niosomes
e. hydrogels
B
Revised Optometry Law of 1995:
a. RA 8203
b. RA 8050
c. RA 10918
d. RA 6675
e. RA 9165
B
- An act regulating and modernizing the practice of pharmacy in the Philippines.
a. RA 8203
b. RA 8050
c. RA 10918
d. RA 6675
e. RA 9165
C
An act to promote, require and ensure the production of an adequate supply, distribution, use and acceptance of
drugs and medicines identified by their generic names.
a. RA 8203
b. RA 8050
c. RA 10918
d. RA 6675
e. RA 9165
D
- An act instituting the Comprehensive Dangerous Drugs Act of 2002.
a. RA 8203
b. RA 8050
c. RA 10918
d. RA 6675
e. RA 9165
E
An act providing for cheaper and quality medicines, amending for the purpose of the intellectual property code, the
generics act and the pharmacy law and for other purposes.
a. RA 8203
b. RA 9502
c. RA 9711
d. RA 7432
e. RA 9165
B
- Drug/s that interacts with beta-blockers; except:
a. cardiac glycosides
b. quinidine
c. xanthines
d. nasal decongestants
e. succinylcholine
E
Drug/s that interacts with beta-blockers, causing cardiac depression; except:
a. cardiac glycosides
b. quinidine
c. xanthines
d. nasal decongestants
e. salbutamol
C
Drugs used to treat open-angle glaucoma that may cause bronchospasm.
a. beta-blockers
b. brimonidine
c. echothiophate
d. pilocarpine
e. cyclopentolate
A